Dual actionability of BMI1 activation and mitotic vulnerability defines adaptive Osimertinib resistance in EGFR-mutant NSCLCPaolo Armanetti, Giorgia Maroni, Chiara Cavallini et al.|Cell Death and Disease|2026Cited by 1
The two sides of resistance: aggressiveness and mitotic instability as the Achilles’ heel of Osimertinib-resistant NSCLCPaolo Armanetti, Giorgia Maroni, Eva Cabrera San Millán et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0